Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 ended September 30, 2026 financial results announced by Iovance Biotherapeutics.
IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 ended September 30, 2026 financial results announced by Iovance Biotherapeutics
- Update on recent corporate and operating developments included in Exhibit 99.1
- Investors should review Exhibit 99.1 for the underlying figures and company outlook
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $121.5M, up ~80% YoY, with U.S. Amtagvi revenue ~$102M, confirming accelerating commercial adoption
- Gross margin ~60%, up from 56% in Q2, while R&D expense declined ~16% sequentially, improving operating leverage
- Net loss narrowed to $22.3M from $91.3M, but nine-month net loss remained $148.6M
- Cash position ~$382M, expected to fund operations well into 2029, reducing near-term financing risk
- mNSCLC data showed 24.6% ORR in 69 patients and 59.1% in a biomarker-selected subgroup, supporting planned 2027 sBLA and pipeline expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings
Get the next IOVA 8-K as it lands
Follow IOVA for push alerts, or ask the research agent what this filing means.